These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26810535)

  • 41. Multiple Sclerosis.
    Reich DS; Lucchinetti CF; Calabresi PA
    N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
    [No Abstract]   [Full Text] [Related]  

  • 42. Disease modifying therapies for relapsing multiple sclerosis.
    Wingerchuk DM; Weinshenker BG
    BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
    Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
    Pawate S; Wang L; Song Y; Sriram S
    J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.
    Dubey D; Cano CA; Stüve O
    Curr Opin Neurol; 2016 Jun; 29(3):272-7. PubMed ID: 27035896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
    Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
    Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relations between mood characteristics, circadian preferences, and functionality in multiple sclerosis.
    Ozdemir PG; Milanlioglu A; Boysan M; Cilingir V; Aydin N; Atli A
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):148-54. PubMed ID: 25363199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].
    Rio J; Rovira A; Blanco Y; Sainz A; Perkal H; Robles R; Ramio-Torrenta L; Diaz RM; Arroyo R; Urbaneja P; Fernandez O; Garcia-Merino JA; Reyes MP; Oreja-Guevara C; Prieto JM; Izquierdo G; Olascoaga J; Alvarez-Cermeno JC; Simon E; Pujal B; Comabella M; Montalban X
    Rev Neurol; 2016 Aug; 63(4):145-50. PubMed ID: 27439483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing response to interferon-β in a multicenter dataset of patients with MS.
    Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
    Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.